Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM

Add to watchlist

$65.16

+23.59

+56.79%

Market closed

Open in about 7 hours

+5.38%

month

+5.38%

quarter

+38.26%

year

Market Cap	1.97B
Enterprise value	897.72M

P/E	-6.22
EV/Sales	11.64
EV/EBITDA	-7.33
Price/Sales	11.98
Price/Book	6.50
PEG ratio	0.13
EPS	-3.76

Revenue	223.99M
EBITDA	-135.23M
Income	-156.05M
Revenue Q/Q	119.07%
Revenue Y/Y	133.89%

Profit margin	-176.05%
Oper. margin	-170.28%
Gross margin	83.94%
EBIT margin	-170.28%
EBITDA margin	-60.37%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Mirum Pharmaceuticals Stock Forecast

M Q Y

Last Year

$57

Potential downside: -12.52%

Analysts Price target
Financials & Ratios estimates

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Profit margin
Jun 2023	37.49M	-74.03M	-197.45%
Sep 2023	47.72M	-23.58M	-49.42%
Dec 2023	69.55M	-33.14M	-47.66%
Mar 2024	69.22M	-25.27M	-36.52%

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Earnings per share (EPS)
2023-08-03	-0.79	-0.84

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Debt to assets
Jun 2023	443588000	364.97M	82.28%
Sep 2023	650642000	381.56M	58.64%
Dec 2023	646621000	397.95M	61.54%
Mar 2024	651962000	417.35M	64.02%

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Cash Flow
Jun 2023	-2.33M	35.54M	114.70M
Sep 2023	-18.22M	-182.76M	207.12M
Dec 2023	-16.61M	-2M	1.77M
Mar 2024	15.21M	-13K	1.20M

Mirum Pharmaceuticals alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Mirum Pharmaceuticals
Employees

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Employee count
Aug 2023	200
Sep 2023	213
Oct 2023	213
Nov 2023	213
Dec 2023	249
Jan 2024	249
Feb 2024	249
Mar 2024	264
Apr 2024	264
May 2024	264
Jun 2024	278
Jul 2024	278

Mirum Pharmaceuticals
Hedge Funds Holdings Q1 2023

21.30% -74.13%

of MIRM is owned by hedge funds

59 -42

hedge funds hold MIRM stock

7.23M -26.09M

shares is hold by hedge funds

MIRM hedge funds holdings changes

Mirum Pharmaceuticals
Insider Trading

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Insider trades (number of shares)
Period	Buy	Sel
Aug 2023	147991	3459
Sep 2023	18437	14216
Dec 2023	0	2500
Jan 2024	0	9572
Feb 2024	0	10599
Mar 2024	4000	4303
Jun 2024	0	35559
Jul 2024	0	375

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	2 Jul 2024	HOWE JOLANDA officer: SVP, GLOBAL CONTROLLER officer: SVP, GLOBAL CONTROLLER	Common Stock	375	$34	$12,750
Option	1 Jul 2024	HOWE JOLANDA officer: SVP, GLOBAL CONTROLLER officer: SVP, GLOBAL CONTROLLER	Common Stock	1,042	N/A	N/A
Option	1 Jul 2024	HOWE JOLANDA officer: SVP, GLOBAL CONTROLLER officer: SVP, GLOBAL CONTROLLER	Restricted Stock Units	1,042	N/A	N/A
Option	24 Jun 2024	VIG PAMELA officer: CHIEF SCIENTIFIC OFFICER officer: CHIEF SCIENTIFIC OFFICER	Stock Option (right to buy)	30,559	$2.94	$89,721
Option	24 Jun 2024	VIG PAMELA officer: CHIEF SCIENTIFIC OFFICER officer: CHIEF SCIENTIFIC OFFICER	Common Stock	30,559	$2.94	$89,721
Sale	24 Jun 2024	VIG PAMELA officer: CHIEF SCIENTIFIC OFFICER officer: CHIEF SCIENTIFIC OFFICER	Common Stock	30,559	$34	$1,039,006
Option	5 Jun 2024	RAMASASTRY SAIRA director director	Common Stock	5,000	$14.12	$70,600
Option	5 Jun 2024	RAMASASTRY SAIRA director director	Stock Option (right to buy)	5,000	$14.12	$70,600
Sale	5 Jun 2024	RAMASASTRY SAIRA director director	Common Stock	5,000	$25.68	$128,400
Purchase	27 Mar 2024	BJERKHOLT ERIC officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Common Stock	2,000	$24.8	$49,600

MIRM insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS FOR TREATING CHOLESTASIS Filling date: 12 Feb 2020 Issue date: 26 May 2022	12 Feb 2020	26 May 2022
Application	Application GENOTYPE AND DOSE-DEPENDENT RESPONSE TO AN ASBTI IN PATIENTS WITH BILE SALT EXPORT PUMP DEFICIENCY Filling date: 12 Feb 2020 Issue date: 5 May 2022	12 Feb 2020	5 May 2022
Application	Application METHODS FOR TREATING CHOLESTASIS Filling date: 17 Dec 2021 Issue date: 7 Apr 2022	17 Dec 2021	7 Apr 2022
Application	Application METHODS FOR TREATING CHOLESTASIS Filling date: 11 Dec 2020 Issue date: 22 Apr 2021	11 Dec 2020	22 Apr 2021
Application	Application METHODS FOR TREATING CHOLESTASIS Filling date: 14 Aug 2020 Issue date: 3 Dec 2020	14 Aug 2020	3 Dec 2020

Mirum Pharmaceuticals
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 5 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 5 Aug 2023	Q2 2023 Earnings Call Transcript

MIRM earnings call transcripts

Mirum Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Christopher Peetz (1979) Pres, Chief Executive Officer & Director	46	$785,220
Dr. Ian Clements (1969) Chief Financial Officer	56	$541,150
Mr. Peter Radovich M.B.A., Ph.D. (1978) Chief Operating Officer	47	$524,850

Mirum Pharmaceuticals
Latest News

Wednesday, 25 December 2024
10:00	Mirum Pharma: Buy At Dips For Volixibat Potential	seekingalpha.com
Thursday, 12 December 2024
12:36	Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?	zacks.com
Tuesday, 10 December 2024
18:00	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Friday, 29 November 2024
11:01	Mirum Shares Surge More Than 90% in 6 Months: Here's Why	zacks.com
Tuesday, 12 November 2024
13:51	Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript	seekingalpha.com
12:45	Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised	zacks.com
10:15	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
Friday, 8 November 2024
18:30	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Thursday, 7 November 2024
16:30	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences	businesswire.com
Monday, 4 November 2024
16:30	Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024	businesswire.com
Thursday, 31 October 2024
11:05	Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know	zacks.com
08:30	Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting	businesswire.com
Thursday, 10 October 2024
19:30	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
08:30	Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis	businesswire.com
Tuesday, 10 September 2024
20:45	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Friday, 6 September 2024
12:37	Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?	zacks.com
Wednesday, 28 August 2024
16:01	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences	businesswire.com
Monday, 19 August 2024
12:11	Mirum (MIRM) Banks on Livmarli, Overdependence a Concern	zacks.com
Friday, 9 August 2024
21:10	Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript	seekingalpha.com
19:00	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	businesswire.com
Thursday, 8 August 2024
12:06	Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top	zacks.com
Wednesday, 7 August 2024
18:25	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
Wednesday, 31 July 2024
16:30	Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024	businesswire.com
Monday, 29 July 2024
08:30	Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?	zacks.com
Wednesday, 17 July 2024
03:48	Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition	seekingalpha.com
Tuesday, 9 July 2024
11:42	Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion	zacks.com
Monday, 8 July 2024
12:40	Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why	zacks.com
Thursday, 27 June 2024
16:48	3 Biotech Stocks For The Second Half Of 2024	seekingalpha.com
Tuesday, 18 June 2024
12:15	Mirum (MIRM) Soars on Interim Data From Liver Disease Studies	zacks.com
06:50	Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?	zacks.com

Ideas & Opinions

Seeking Alpha 4 May 2025

Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities
Seeking Alpha 8 Jan 2025

Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)
Seeking Alpha 25 Dec 2024

Mirum Pharmaceuticals: Buy At Dips For Volixibat Potential
Seeking Alpha 27 Jun 2024

3 Biotech Stocks For The Second Half Of 2024
Seeking Alpha 22 Apr 2024

Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Seeking Alpha 19 Dec 2023

Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss
Seeking Alpha 24 Sep 2023

Mirum Pharmaceuticals: An Attractive Stock To Watch For Its Liver Disease Franchise
Seeking Alpha 9 Jul 2023

Mirum: Must Watch Biotech On Release Of Results From EMBARK Study
Seeking Alpha 1 Feb 2023

Mirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo Pharma
Seeking Alpha 20 Nov 2022

Mirum: Potential For European Approval To Move It Forward

Frequently Asked Questions (FAQ)

What's the price of Mirum Pharmaceuticals stock today?

One share of Mirum Pharmaceuticals stock can currently be purchased for approximately $65.16.
When is Mirum Pharmaceuticals's next earnings date?

Unfortunately, Mirum Pharmaceuticals's (MIRM) next earnings date is currently unknown.
Does Mirum Pharmaceuticals pay dividends?

No, Mirum Pharmaceuticals does not pay dividends.
How much money does Mirum Pharmaceuticals make?

Mirum Pharmaceuticals has a market capitalization of 1.97B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 141.85% to 186.37M US dollars. Mirum Pharmaceuticals made a loss 163.42M US dollars in net income (profit) last year or -$0.84 on an earnings per share basis.
What is Mirum Pharmaceuticals's stock symbol?

Mirum Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "MIRM".
What is Mirum Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Mirum Pharmaceuticals?

Shares of Mirum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Mirum Pharmaceuticals's key executives?
Mirum Pharmaceuticals's management team includes the following people:
- Mr. Christopher Peetz Pres, Chief Executive Officer & Director(age: 46, pay: $785,220)
- Dr. Ian Clements Chief Financial Officer(age: 56, pay: $541,150)
- Mr. Peter Radovich M.B.A., Ph.D. Chief Operating Officer(age: 47, pay: $524,850)
How many employees does Mirum Pharmaceuticals have?

As Jul 2024, Mirum Pharmaceuticals employs 278 workers, which is 5% more then previous quarter.
When Mirum Pharmaceuticals went public?

Mirum Pharmaceuticals, Inc. is publicly traded company for more then 6 years since IPO on 18 Jul 2019.
What is Mirum Pharmaceuticals's official website?

The official website for Mirum Pharmaceuticals is mirumpharma.com.
Where are Mirum Pharmaceuticals's headquarters?

Mirum Pharmaceuticals is headquartered at 950 Tower Lane, Foster City, CA.
How can i contact Mirum Pharmaceuticals?

Mirum Pharmaceuticals's mailing address is 950 Tower Lane, Foster City, CA and company can be reached via phone at +65 06674085.
What is Mirum Pharmaceuticals stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Mirum Pharmaceuticals in the last 12 months, the avarage price target is $57. The average price target represents a -12.52% change from the last price of $65.16.

Mirum Pharmaceuticals, Inc.

mirumpharma.com

Exchange:

NASDAQ

Full time employees:

311

Industry:

Biotechnology

Sector:

Healthcare

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

+65 06674085

950 Tower Lane
Foster City, CA 94404

CIK: 0001759425
ISIN: US6047491013
CUSIP: 604749101